Enanta Pharmaceuticals Inc (ENTA NASDAQ) stock market data APIs
$7.5675
-0.05(-0.7%)
as of June 30, 2025
Try our APIs with
free plan!
Enanta Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Prev. Close
7.5675
Open
7.5199
High
7.5781
Low
7.3008
52 wk Range
4.09-17.235
Market Cap
160 M
Shares Outstanding
21 377 K
Revenue
64 463 K
EPS
-1.06
Beta
0.772
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Enanta Pharmaceuticals Inc data using free add-ons & libraries
Get Enanta Pharmaceuticals Inc Fundamental Data
Enanta Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 64 463 K
- EBITDA: -98 944 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: -1.136
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Enanta Pharmaceuticals Inc News
New
XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform
CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree ...
Enanta Pharmaceuticals' SWOT analysis: stock shifts focus to immunology amid RSV progress
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a biotechnology company specializing in small molecule drugs for viral infections and liver diseases, is undergoing a strategic shift towards immunology whi...
AbbVie Secures FDA Approval to Expand Mavyret’s Label
AbbVie Inc. (NYSE:ABBV) is one of the best stocks for a dividend stock portfolio. The company announced that the US FDA has expanded the approved use of its oral antiviral drug Mavyret, developed in ...
FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection
The U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie Inc’s (NYSE:ABBV) Mavyret (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy. ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
